Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Mandatory Switching Policies More Effectively Increase Uptake of Biosimilars
February 14th 2023Pharmaceutical claims data were collected for the reference drugs and etanercept and infliximab biosimilars to analyze changes in the proportions of dispensed of and total spending on biosimilars after the new start and biosimilar switching policies began.
Read More
Mobile Health Systems Improve Pain Intensity, Quality of Life in Patients with Chronic Pain
February 8th 2023The systematic review compared mHealth interventions with conventional treatment or nonintervention to determine the pain management effects of mobile-based self-management strategies.
Read More
Significant Decreases in Tophus, Double Contour Sign Observed in Patients With Gout Receiving ULT
February 6th 2023Musculoskeletal ultrasound evaluated tophus size and double contour sign in lower extremity joints of patients with gout before and after initiating uric acid lowering therapy.
Read More
DECT Scoring System Proves to be a Noninvasive, Effective Tool for Gout Diagnosis
February 6th 2023The DECT scoring system obtained excellent diagnostic performance for differentiating early-stage gout from middle-stage gout, with sensitivity, positive and negative predictive values, and specificity all achieving an accuracy of > 85%.
Read More
Multidisciplinary Lifestyle Program Decreased Disease Activity in Patients With Rheumatoid Arthritis
February 3rd 2023“Reversing and preventing adverse lifestyle factors could potentially reduce the incidence and burden of rheumatoid arthritis, as well as alleviate its comorbidities,” investigators hypothesized.
Read More
Infliximab Biosimilar Competition did not Improve Affordability for Patients
February 1st 2023Investigators evaluated whether the availability of the biosimilar infliximab was linked to lower out-of-pocket costs using claims from the IBM MarketScan national data set of commercially insured patients.
Read More
Biomarker Predicts Patients at Greater Risk of Worsening Knee Osteoarthritis
January 30th 2023“Our primary motivation was to help develop treatments for people with osteoarthritis that would slow or prevent the disease and be more than painkillers- actually affect the disease process itself,” Virginia Kraus, MD, explains.
Read More
Rheumatology Month in Review: January 2023
January 29th 2023The January 2023 rheumatology month in review highlights a recent study that indicated an increased risk of hospitalization and death among patients with gout and COVID-19, the expansion of research evaluating adalimumab biosimilars, and trends in fibromyalgia.
Read More